Percutaneous Excision Trial

NCT ID: NCT00720642

Last Updated: 2012-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1170 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-07-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To confirm that a definitive diagnosis can be made from the tissue sample collected using the Intact BLES when defined radiology and pathology criteria are met.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Imaged Breast Abnormalities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PSAP

This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.

No interventions assigned to this group

NPSAP

Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must be a female at least 18 years of age at the time of Intact BLES biopsy
* Patient must have had an imaged abnormality found via mammography or sonography that warrants a biopsy for further diagnosis

Exclusion Criteria

* Patients who have pre-pectoral breast implants
* Patients who have implantable devices such as pacemakers and defibrillators
* Patients who are pregnant or lactating
* Patients in whom the device is contraindicated
* Patients who are contraindicated for surgery due to factors such as anti-coagulant use which cannot be safely reversed or who exhibit fever or other clinical evidence of infection
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Intact Medical Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas for Medical Services

Little Rock, Arkansas, United States

Site Status

The Breast Health Center

Indio, California, United States

Site Status

Long Beach Memorial Breast Center

Long Beach, California, United States

Site Status

The Hill Breast Center

Pasadena, California, United States

Site Status

Flagler Hospital

Saint Augustine, Florida, United States

Site Status

Center for Breast Care HCA

West Palm Beach, Florida, United States

Site Status

Metro Surgical Associates, Inc.

Lithonia, Georgia, United States

Site Status

TIFT Regionald Medical Center

Tifton, Georgia, United States

Site Status

Maui Medical Group

Wailuku, Hawaii, United States

Site Status

Shawnee Mission Medical Center

Overland Park, Kansas, United States

Site Status

St. Joseph Medical Center

Towson, Maryland, United States

Site Status

Mercy Medical Center

Springfield, Massachusetts, United States

Site Status

Genesys Medical Center

Grand Blanc, Michigan, United States

Site Status

Saint Luke's Cancer Institute

Kansas City, Missouri, United States

Site Status

Lourdes Hospital Breast Center

Binghamton, New York, United States

Site Status

Wilson Hospital Breast Center

Johnson City, New York, United States

Site Status

Jewish Hospital Breast Center

Cincinnati, Ohio, United States

Site Status

University of Cincinnati The Barrett Center

Cincinnati, Ohio, United States

Site Status

Elyria Memorial Hospital

Elyria, Ohio, United States

Site Status

St. John West Shore Hospital

Westlake, Ohio, United States

Site Status

Evangelical Hospital

Lewisburg, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Coastal Carolina Breast Center

Murrells Inlet, South Carolina, United States

Site Status

Nashville Breast Center

Nashville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Intact 06-06

Identifier Type: -

Identifier Source: org_study_id